AU2006210895A1 - Compositions containing the anti-angiogenic PHSCN-peptide - Google Patents

Compositions containing the anti-angiogenic PHSCN-peptide Download PDF

Info

Publication number
AU2006210895A1
AU2006210895A1 AU2006210895A AU2006210895A AU2006210895A1 AU 2006210895 A1 AU2006210895 A1 AU 2006210895A1 AU 2006210895 A AU2006210895 A AU 2006210895A AU 2006210895 A AU2006210895 A AU 2006210895A AU 2006210895 A1 AU2006210895 A1 AU 2006210895A1
Authority
AU
Australia
Prior art keywords
composition
peptide
acid
analogue
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006210895A
Other languages
English (en)
Inventor
Scott Harris
Hashem Heiati
Ming Li
Andrew P. Mazar
Jay Schrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactic Pharma LLC
Original Assignee
Attenuon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon LLC filed Critical Attenuon LLC
Publication of AU2006210895A1 publication Critical patent/AU2006210895A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2006210895A 2005-02-01 2006-02-01 Compositions containing the anti-angiogenic PHSCN-peptide Abandoned AU2006210895A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64839105P 2005-02-01 2005-02-01
US60/648,391 2005-02-01
PCT/US2006/003461 WO2006083906A2 (fr) 2005-02-01 2006-02-01 Préparations améliorées de peptides anti-angiogéniques

Publications (1)

Publication Number Publication Date
AU2006210895A1 true AU2006210895A1 (en) 2006-08-10

Family

ID=36581633

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006210895A Abandoned AU2006210895A1 (en) 2005-02-01 2006-02-01 Compositions containing the anti-angiogenic PHSCN-peptide

Country Status (6)

Country Link
EP (1) EP1843779A2 (fr)
JP (1) JP2008528630A (fr)
KR (1) KR20070100832A (fr)
AU (1) AU2006210895A1 (fr)
CA (1) CA2596255A1 (fr)
WO (1) WO2006083906A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US9340580B2 (en) 2007-08-15 2016-05-17 Circassia Limited Peptide with multiple epitopes
CN101503458B (zh) * 2008-02-04 2012-05-09 上海市第一人民医院 预防和治疗血管新生的小分子多肽及其应用
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
WO2011066386A1 (fr) * 2009-11-25 2011-06-03 Novetide, Ltd. Procédé de production de degarelix
HUE043367T2 (hu) * 2013-11-07 2019-08-28 Dr August Wolff Gmbh & Co Kg Arzneimittel Tárolás során stabil liofilizált tripeptid készítmények
EA202190249A1 (ru) * 2018-07-11 2021-05-21 Иммунити Фарма Лтд. Пептидные соединения и их терапевтическое применение

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140010A (en) * 1989-09-28 1992-08-18 Immunobiology Research Institute Stabilized aqueous formulations of thymopentin
AU7302298A (en) * 1996-11-21 1998-06-10 Regents Of The University Of Michigan, The Invasion-inducing agents and invasion-inhibitors for use in wound healing and cancer
PL377763A1 (pl) * 2002-11-25 2006-02-20 Attenuon, Llc. Peptydy, które hamują angiogenezę, migrację komórek, naciekanie komórkowe i proliferację komórkową oraz kompozycje zawierające te peptydy i ich zastosowania

Also Published As

Publication number Publication date
JP2008528630A (ja) 2008-07-31
CA2596255A1 (fr) 2006-08-10
WO2006083906A2 (fr) 2006-08-10
EP1843779A2 (fr) 2007-10-17
KR20070100832A (ko) 2007-10-11
WO2006083906A3 (fr) 2006-10-05

Similar Documents

Publication Publication Date Title
AU2006210895A1 (en) Compositions containing the anti-angiogenic PHSCN-peptide
RU2518240C2 (ru) Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
JP5597271B2 (ja) 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
CA2156255C (fr) Dispositif a semi-conducteur
FI85335C (fi) Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition.
CN105899242B (zh) 包含聚合抑制剂的一组分纤维蛋白胶
KR100705997B1 (ko) 안정화된 hgf 동결건조제제 및 그 제조방법
CA2624173A1 (fr) Preparations pharmaceutiques
US10456443B2 (en) Peptidyl calcineurin inhibitors
AU3452799A (en) Local delivery of long lasting therapeutic agents
US20030170250A1 (en) Local delivery of long lasting therapeutic agents
TW200538466A (en) Methods for controlling angiogenesis and cell proliferation
AU9723198A (en) Human growth hormone-containing aqueous pharmaceutical composition
JP2015221835A (ja) α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
PT1196433E (pt) Derivados de peptidos ciclicos como inibidores da integrina clvbg
PT1029548E (pt) Método para manutenção da qualidade de uma solução parentérica de trombomodulina em armazenamento e distribuição.
ES2327982T3 (es) Inhibidores de la invasion para su utilizacion en la cicatrizacion de heridas y cancer.
AU771099B2 (en) Inhibitors of the integrin alphavbeta6
KR20070100411A (ko) Ａｃ－ＰＨＳＣＮ－ＮＨ２의 산 부가 염
EP3333177B1 (fr) Composé multicible présentant une activité d'anticoagulation et antiplaquettaire, son procédé de préparation et son utilisation
US6335320B1 (en) Method of treating fibrotic conditions
AU1360999A (en) Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
CN101262888A (zh) Pyy的增强粘膜递送的制剂
MXPA05008313A (es) Sulfonamidas peptidicas.
AU2013211463A1 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application